Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy
Malignant melanoma is a devastating disease whose incidences are continuously rising. The recently approved antimelanoma therapies carry new hope for metastatic patients for the first time in decades. However, the clinical management of melanoma is severely hampered by the absence of effective scree...
Saved in:
Main Authors: | R. Ortenberg, S. Sapoznik, D. Zippel, R. Shapira-Frommer, O. Itzhaki, A. Kubi, D. Zikich, M. J. Besser, J. Schachter, G. Markel |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2015/902137 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients
by: Sapoznik Sivan, et al.
Published: (2012-01-01) -
Focus on Adoptive T Cell Transfer Trials in Melanoma
by: Liat Hershkovitz, et al.
Published: (2010-01-01) -
A Full GMP Process to Select and Amplify Epitope-Specific T Lymphocytes for Adoptive Immunotherapy of Metastatic Melanoma
by: N. Labarriere, et al.
Published: (2013-01-01) -
Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients
by: Amalia Azzariti, et al.
Published: (2025-02-01) -
Progress in immunotherapy for brain metastatic melanoma
by: Shicheng Zheng, et al.
Published: (2025-01-01)